EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High expression of DEC2 distinguishes chondroblastic osteosarcoma and promotes tumour growth by activating the VEGFC/VEGFR2 signalling pathway

Maimaitiaili Tuerxun iD, Xu Zheng, Jun Xu, Quanjun Yang, Ting Yuan, Changqing Zhang, Shumin Zhou

Journal of Cellular and Molecular Medicine · 2024

DOI: 10.1111/jcmm.18462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Maimaitiaili Tuerxun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Bone Neoplasms, Cell Proliferation, Gene Expression Regulation, Neoplastic, Osteosarcoma. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Research Plan of SHDC, Basic Scientific Research Projects of Shanghai Sixth People's Hospital, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma (OS) is the most common primary malignant bone tumour in children and young adults. Account for 80% of all OS cases, conventional OS are characterized by the presence of osteoblastic, chondroblastic and fibroblastic cell types. Despite this heterogeneity, therapeutic treatment and prognosis of OS are essentially the same for all OS subtypes. Here, we report that DEC2, a transcriptional repressor, is expressed at higher levels in chondroblastic OS compared with osteoblastic OS. This difference suggests that DEC2 is disproportionately involved in the progression of chondroblastic OS, and thus, DEC2 may represent a possible molecular target for treating this type of OS. In the human chondroblastic‐like OS cell line MNNG/HOS, we found that overexpression of DEC2 affects the proliferation of the cells by activating the VEGFC/VEGFR2 signalling pathway. Enhanced expression of DEC2 increased VEGFR2 expression, as well as increased the phosphorylation levels at sites Y951 and Y1175 of VEGFR2. On the one hand, activation of VEGFR2 Y1175 enhanced cell proliferation through VEGFR2 Y1175 ‐PLCγ1‐PKC‐SPHK‐MEK‐ERK signalling. On the other hand, activation of VEGFR2 Y951 decreased mitochondria‐dependent apoptosis rate through VEGFR2 Y951 ‐VARP‐PI3K‐AKT signalling. Activation of these two signalling pathways resulted in enhanced progression of chondroblastic OS. In conclusion, DEC2 plays a pivotal role in cell proliferation and apoptosis‐resistance in chondroblastic OS via the VEGFC/VEGFR2 signalling pathway. These findings lay the groundwork for developing focused treatments that target specific types of OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsCell ProliferationGene Expression Regulation, NeoplasticOsteosarcomaVascular Endothelial Growth Factor CVascular Endothelial Growth Factor Receptor-2Basic Helix-Loop-Helix ProteinsAnimalsHumansApoptosisCell Line, TumorPhosphorylationSignal Transduction

Stichwörter der Autor:innen

Chondroblastic osteosarcomaDEC2VEGF signallingphosphorylation

Substanzen

Vascular Endothelial Growth Factor CVascular Endothelial Growth Factor Receptor-2Basic Helix-Loop-Helix ProteinsKDR protein, humanVEGFC protein, humanBHLHE41 protein, human

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Pharmacy, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Institute of Microsurgery on Extremities, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Maimaitiaili Tuerxun

Förderung

  • Clinical Research Plan of SHDC
  • Basic Scientific Research Projects of Shanghai Sixth People's Hospital
  • National Natural Science Foundation of China

Zitieren

APA

Tuerxun, M., Zheng, X., Xu, J., Yang, Q., Yuan, T., Zhang, C., & Zhou, S. (2024). High expression of DEC2 distinguishes chondroblastic osteosarcoma and promotes tumour growth by activating the VEGFC/VEGFR2 signalling pathway. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18462

Vancouver

Tuerxun M, Zheng X, Xu J, Yang Q, Yuan T, Zhang C, et al. High expression of DEC2 distinguishes chondroblastic osteosarcoma and promotes tumour growth by activating the VEGFC/VEGFR2 signalling pathway. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18462

BibTeX
@article{Tuerxun2024,
  author = {Tuerxun, Maimaitiaili and Zheng, Xu and Xu, Jun and Yang, Quanjun and Yuan, Ting and Zhang, Changqing and Zhou, Shumin},
  title = {High expression of DEC2 distinguishes chondroblastic osteosarcoma and promotes tumour growth by activating the VEGFC/VEGFR2 signalling pathway},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.18462}
}
Kostenlos starten →